Cohance Lifesciences Share Price in Focus; USFDA Inspection at Shamshabad Plant Ends With Four Observations

Cohance Lifesciences share price will be in focus after the US Food and Drug Administration completed its inspection of the company's formulation plant at Shamshabad, Telangana. The inspection started on August 27 and ended on September 4, 2026. 

USFDA Inspection at Shamshabad Plant 

The USFDA inspected Cohance Lifesciences' formulation facility at Shamshabad over a period of nine days. 

The inspection ended with the USFDA issuing a Form FDA 483 with four observations. The company said it has started working on corrective and preventive actions and will send its response within the given timeline. 

Company to Respond to Observations 

Cohance Lifesciences will submit its response to the USFDA within the stipulated timeline. The company also said that it remains focused on quality and meeting regulatory requirements. 

Read More: Hilton Expands India Presence With 60 Hotels Under Construction, Plans 400 More Properties! 

Cohance Lifesciences Share Price Performance 

As of September 04, 2026, Cohance Lifesciences share price closed at ₹456.60 per share, reflecting a decline of 0.92% from the previous trading session 

Conclusion 

The USFDA inspection of Cohance Lifesciences' Shamshabad formulation plant has been completed with four observations. The company has started corrective and preventive action and will submit its response within the required timeline. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.